Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Investment analysts at SunTrust Banks raised their Q3 2017 earnings per share (EPS) estimates for Ekso Bionics Holdings in a research note issued to investors on Monday. SunTrust Banks analyst B. Nudell now forecasts that the company will post earnings of ($0.13) per share for the quarter, up from their previous forecast of ($0.15). SunTrust Banks also issued estimates for Ekso Bionics Holdings’ FY2017 earnings at ($0.64) EPS, FY2018 earnings at ($0.32) EPS and FY2021 earnings at ($0.17) EPS.
Ekso Bionics Holdings (NASDAQ:EKSO) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.38 million. Ekso Bionics Holdings had a negative net margin of 372.20% and a negative return on equity of 798.93%.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/12/q3-2017-eps-estimates-for-ekso-bionics-holdings-inc-boosted-by-analyst-nasdaqekso.html.
A number of other research firms also recently commented on EKSO. B. Riley reiterated a “buy” rating and set a $4.00 price objective on shares of Ekso Bionics Holdings in a research note on Monday, May 15th. Zacks Investment Research upgraded shares of Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Wednesday, July 26th.
Shares of Ekso Bionics Holdings (NASDAQ EKSO) opened at 1.47 on Thursday. The stock’s 50 day moving average is $1.99 and its 200 day moving average is $2.64. Ekso Bionics Holdings has a 52-week low of $0.99 and a 52-week high of $6.38. The stock’s market capitalization is $37.91 million.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Ekso Bionics Holdings by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after buying an additional 176,197 shares during the period. National Planning Corp increased its position in Ekso Bionics Holdings by 116.2% in the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after buying an additional 126,000 shares during the period. Carl Domino Inc increased its position in Ekso Bionics Holdings by 74.7% in the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after buying an additional 35,088 shares during the period. Finally, Independence Advisors LLC bought a new position in Ekso Bionics Holdings during the second quarter worth approximately $1,840,000. Hedge funds and other institutional investors own 4.55% of the company’s stock.
What are top analysts saying about Ekso Bionics Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ekso Bionics Holdings Inc. and related companies.